Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Dr Anton_Invests Profile picture
Dr Anton_Invests
@seahorse_anton
Ex Neuroscientist - Data Science AI + ML | Equity Research | Building Prediction Models | My Deep Research - Opinions, Not Financial Advice
Dec 27 • 15 tweets • 14 min read
🧵Dive Deep 🙇‍♂️: Prime Medicine $PRME — The Next Generation of Gene Editing - Part 1

1. 🧬 The Prime Medicine Story: Search and Replace
Prime Medicine is at the forefront of the gene editing revolution, founded on a breakthrough technology designed to correct the genetic causes of disease with unprecedented precision.

The Genesis of Prime Editing
The company’s story begins not in a boardroom, but in a research lab, emerging from one of the most prestigious scientific institutions in the world.

Technology Origin: Prime Editing technology was developed in the lab of Dr. David R. Liu (Co-Founder and Member of Scientific Advisory Board) and Dr. Andrew Anzalone (Co-Founder and Head of Prime Editing Platform) at the Broad Institute of MIT and Harvard.

Scientific Breakthrough: The core research describing Prime Editing was published in the journal Nature in December 2019.
nature.com/articles/s4158…

Company Founding Year: The company, Prime Medicine, Inc., was formally founded in 2019 in Cambridge, Massachusetts, to translate this groundbreaking science into curative medicines.

💡 The Vision: The scientific founders conceived of “Prime Editing” as a genetic search-and-replace function, aiming to improve on earlier CRISPR-based editing by making precise changes to DNA without causing a double-strand break, which is a major source of unwanted errors.Image Key Founding & Early Leadership
The company quickly attracted seasoned biotech veterans to lead its translation from the lab bench to the patient bedside.

Scientific Founders: Dr. David R. Liu and Dr. Andrew Anzalone.

Early CEO: Dr. Keith Gottesdiener served as the President and CEO during the initial launch and growth phases.

Current Leadership: As of mid-2025, the leadership transitioned, with Dr. Allan Reine (M.D.) becoming the Chief Executive Officer, and Jeffrey Marrazzo (M.B.A., M.P.A.) taking the role of Executive Chair.

Founded Year 2019

Launch/Major Funding: The company officially “launched” in July 2021 with an impressive $315 million in financing.
Employee Count: As of late 2024, the company had approximately 214 employees. Headquarters - Cambridge, Massachusetts, USA.